Patient-Relevant Bleeding Events Among Patients Taking Anticoagulant Medication was recently presented at the International Society on Thrombosis and Haemostasis’ (ISTH) annual meeting in Montreal. Anthos Therapeutics, in collaboration with StopAfib.org and the National Blood Clot Alliance (NBCA), presented new data from a survey of afib and VTE patients about the impact of so-called “minor bleeding” on …
Read More
Patients with atrial fibrillation are at higher risk of suffering stroke and other complications related to the development of blood clots in their heart. Until 2010, the only oral anticoagulant (blood thinner) to prevent strokes in Afib was warfarin (Coumadin®). Now there are two new oral anticoagulants available in the United States--dabigatran (Pradaxa®) and rivaroxaban …
Read More
The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed …
Read More